ClinicalTrials.gg
CompletedNCT00783094Updated Mar 29, 2011Results posted

Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension

A Phase 2 interventional study of Tadalafil 2.5 mg and Tadalafil 5 mg in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 6 sites in Japan. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2011-03-29.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
9th of 26
422 · median 258
Started
2008
the only one that year
Phase 2
4 of 26
none open now
Registered
5th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 9th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 2, and was the 5th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the long-term safety and efficacy of tadalafil in Japanese men with signs and symptoms of benign prostatic hyperplasia.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese Males, 45 years old or older, with benign prostatic hyperplasia (BPH) for at least 6 months prior to Visit 1 and an International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 2.
  • Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED), and/or overactive bladder (OAB) treatments at any time during the study.
  • Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any other BPH therapy, ED or OAB therapy for specified duration of time prior to Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Prostate specific antigen (PSA) score beyond acceptable range defined for study at Visit 1.
  • History of urinary retention or lower urinary tract (bladder) stones within 6 months of Visit 1.
  • History of urethral obstruction due to stricture, valves, sclerosis, or tumor at Visit 1.
  • Clinical evidence of prostate cancer at Visit 1.
  • Clinical evidence of any of the bladder or urinary tract conditions, which may affect lower urinary tract symptom at Visit 1.
  • History of cardiac conditions, including Angina requiring certain treatment with nitrates, unstable angina defined for study, positive cardiac stress test before starting the study.
  • History of significant central nervous system (CNS) injuries (including stroke or spinal cord injury) within 6 months of Visit 1.
  • Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens, luteinizing hormone-releasing hormone (LHRH) agonists/antagonists, or anabolic steroids at Visit 1.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
422 participants (actual)

Study arms

  • Experimental
    Tadalafil 2.5 milligrams (mg)

    2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.

    Drug: Tadalafil 2.5 mg

  • Experimental
    Tadalafil 5 mg

    5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.

    Drug: Tadalafil 5 mg

  • Placebo comparator
    Placebo

    Placebo tablet taken by mouth once a day for 12 weeks. Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint

    The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint

    IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.

    Time frame: Baseline, 12 weeks

  2. Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint

    IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.

    Time frame: Baseline, 12 weeks

  3. Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint

    Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).

    Time frame: Baseline, 12 weeks

  4. Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint

    The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.

    Time frame: Baseline, 12 weeks

  5. Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint

    Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).

    Time frame: Baseline, 12 weeks

  6. Tadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement

    Plasma from participants in the tadalafil treatment groups were assayed using a validated liquid chromatographic/mass spectrometric (LC/MS) method.

    Time frame: Baseline, 12 weeks

  7. Number of Participants With Adverse Events During 12 Weeks of the Study

    A listing of Adverse Events are reported in the Reported Adverse Event Section.

    Time frame: Baseline through 12 weeks

  8. Change From Baseline in Blood Pressure at 12-Week Endpoint

    Time frame: Baseline, 12 weeks

  9. Change From Baseline in Sitting Heart Rate at 12-Week Endpoint

    Time frame: Baseline, 12 Weeks

  10. Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint

    Postvoid residual volume (PVR) is measured by ultrasound at regular intervals.

    Time frame: Baseline, 12 weeks

  11. Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint

    Measurement of nanograms of PSA per milliliter (ng/mL) of blood.

    Time frame: Baseline, 12 weeks

  12. Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint

    The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

    Time frame: Baseline, 54 weeks

  13. Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint

    IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.

    Time frame: Baseline, 54 weeks

  14. Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint

    IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.

    Time frame: Baseline, 54 weeks

  15. Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint

    Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).

    Time frame: Baseline, 54 weeks

  16. Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint

    The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.

    Time frame: Baseline, 54 weeks

  17. Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint

    Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).

    Time frame: Baseline, 54 weeks

  18. Number of Participants With Adverse Events During 42 Weeks of Open-Label Treatment

    A listing of Adverse Events are reported in the Reported Adverse Event Section.

    Time frame: End of 12 weeks of double-blind through 54 weeks

  19. Change From Baseline in Blood Pressure During at 54-Week Endpoint

    Time frame: Baseline, 54 weeks

  20. Change From Baseline in Sitting Heart Rate at 54-Week Endpoint

    Time frame: Baseline, 54-weeks

  21. Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint

    Measurement of nanograms of PSA per milliliter (ng/mL) of blood.

    Time frame: Baseline, 54 weeks

  22. Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint

    Post residual volume (PVR) is measured by ultrasound at regular intervals.

    Time frame: Baseline, 54 weeks

07

Results

Posted Jul 28, 2010

Participant flow

Randomized Double-Blind Treatment Period
Participant flow — Randomized Double-Blind Treatment Period
MilestoneTadalafil 2.5 mgTadalafil 5 mgPlacebo
Started142140140
Completed135128131
Not completed7129
Withdrew: Adverse event455
Withdrew: Lack of efficacy021
Withdrew: Physician decision020
Withdrew: Protocol violation121
Withdrew: Withdrawal by subject212
Open-Label Extension Period
Participant flow — Open-Label Extension Period
MilestoneTadalafil 2.5 mgTadalafil 5 mgPlacebo
Started135128131
Completed113109101
Not completed221930
Withdrew: Adverse event12716
Withdrew: Death001
Withdrew: Protocol violation457
Withdrew: Withdrawal by subject113
Withdrew: Physician decision423
Withdrew: Lack of efficacy140

Outcome measures

PrimaryChange From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint

The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in International Prostate Symptom Score (IPSS) Total Score at 12-Week Endpoint-4.5 ± 0.4-4.9 ± 0.4-3.8 ± 0.4
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = 0.201 · Mean difference (final values): -0.7 · 95% CI -1.8 to 0.4Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = 0.062 · Mean difference (final values): -1.1 · 95% CI -2.2 to 0.1Least Squares Mean Difference = Tadalafil 5 mg - Placebo.
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint

IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12-Week Endpoint-1.6 ± 0.2-1.6 ± 0.2-1.4 ± 0.2
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = 0.356 · Mean difference (final values): -0.2 · 95% CI -0.7 to 0.2Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = 0.487 · Mean difference (final values): -0.2 · 95% CI -0.6 to 0.3Least Squares Mean Difference = Tadalafil 5 mg - Placebo.
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint

IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12-Week Endpoint-2.9 ± 0.3-3.3 ± 0.3-2.4 ± 0.3
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = 0.228 · Mean difference (final values): -0.5 · 95% CI -1.3 to 0.3Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = 0.033 · Mean difference (final values): -0.9 · 95% CI -1.7 to -0.1Least Squares Mean Difference = Tadalafil 5 mg - Placebo.
SecondaryChange From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint

Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in IPSS Quality of Life (QoL) Index at 12-Week Endpoint-0.5 ± 0.1-0.7 ± 0.1-0.4 ± 0.1
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = 0.249 · Mean difference (final values): -0.2 · 95% CI -0.4 to 0.1Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = 0.022 · Mean difference (final values): -0.3 · 95% CI -0.6 to -0.0Least Squares Mean Difference = Tadalafil 5 mg - Placebo.
SecondaryChange From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint

The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 12-Week Endpoint-0.7 ± 0.1-0.8 ± 0.1-0.7 ± 0.1
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = 0.904 · Mean difference (final values): -0.0 · 95% CI -0.4 to 0.3Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = 0.800 · Mean difference (final values): -0.0 · 95% CI -0.4 to 0.3With effects for treatment, BPH severity(moderate/severe), prior alpha blocker use (yes/no), and baseline value.
SecondaryChange From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint

Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · milliliters per second
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint
milliliters per secondTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12-Week Endpoint0.7 ± 0.30.6 ± 0.31.4 ± 0.3
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · ANCOVA · p = 0.147 · Mean difference (final values): -0.6 · 95% CI -1.5 to 0.2Least Squares Mean Difference = Tadalafil 2.5 mg - Placebo.
  • Tadalafil 5 mg vs Placebo · ANCOVA · p = 0.094 · Mean difference (final values): -0.7 · 95% CI -1.6 to 0.1Least Squares Mean Difference = Tadalafil 5 mg - Placebo.
SecondaryTadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement

Plasma from participants in the tadalafil treatment groups were assayed using a validated liquid chromatographic/mass spectrometric (LC/MS) method.

Time frame:
Baseline, 12 weeks
Reported as:
Geometric mean · nanogram/milliliter
Tadalafil Pharmacokinetics in Japanese Men: Plasma Concentration Measurement
nanogram/milliliterTadalafil 2.5 mgTadalafil 5 mg
0-6 hours (n=225, 200)86.0 ± 44.0169 ± 41.2
6-12 hours (n=72, 72)68.7 ± 37.6140 ± 51.3
12-24 hours (n=102, 106)57.5 ± 49.193.6 ± 55.6
24-48 hours (n=11, 8)43.5 ± 89.775.2 ± 56.0
SecondaryNumber of Participants With Adverse Events During 12 Weeks of the Study

A listing of Adverse Events are reported in the Reported Adverse Event Section.

Time frame:
Baseline through 12 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events During 12 Weeks of the Study
participantsTadalafil 2.5 mgTadalafil 5 mgPlacebo
Serious Adverse Events221
Non-Serious Adverse Events525453
SecondaryChange From Baseline in Blood Pressure at 12-Week Endpoint
Time frame:
Baseline, 12 weeks
Reported as:
Mean · mmHg
Change From Baseline in Blood Pressure at 12-Week Endpoint
mmHgTadalafil 2.5 mgTadalafil 5 mgPlacebo
Systolic Blood Pressure-2.0 ± 11.9-3.4 ± 12.2-0.5 ± 14.0
Diastolic Blood Pressure-0.7 ± 9.5-2.9 ± 8.3-0.9 ± 10.1
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · Wilcoxin rank-sum test · p = 0.342 (P-Value for systolic blood pressure.)
  • Tadalafil 5 mg vs Placebo · Wilcoxin rank sum test · p = 0.127 (P-Value for systolic blood pressure.)
  • Tadalafil 2.5 mg vs Placebo · Wilcoxin rank-sum test · p = 0.705 (P-Value for diastolic blood pressure.)
  • Tadalafil 5 mg vs Placebo · Wilcoxin rank-sum test · p = 0.173 (P-Value for diastolic blood pressure.)
SecondaryChange From Baseline in Sitting Heart Rate at 12-Week Endpoint
Time frame:
Baseline, 12 Weeks
Reported as:
Mean · beats per minute
Change From Baseline in Sitting Heart Rate at 12-Week Endpoint
beats per minuteTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Sitting Heart Rate at 12-Week Endpoint-0.7 ± 9.9-1.2 ± 9.80.0 ± 8.2
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · Wilcoxin rank-sum test · p = 0.606
  • Tadalafil 5 mg vs Placebo · Wilcoxin rank-sum test · p = 0.149
SecondaryChange From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint

Postvoid residual volume (PVR) is measured by ultrasound at regular intervals.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · milliliters
Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint
millilitersTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Postvoid Residual Volume (PVR) at 12-Week Endpoint-9.41 ± 41.43-5.15 ± 40.32-4.72 ± 36.40
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · Wilcoxin rank-sum test · p = 0.428
  • Tadalafil 5 mg vs Placebo · Wilcoxin rank-sum test · p = 0.426
SecondaryChange From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint

Measurement of nanograms of PSA per milliliter (ng/mL) of blood.

Time frame:
Baseline, 12 weeks
Reported as:
Mean · Micrograms per liter
Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint
Micrograms per literTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Prostate Specific Antigen (PSA) at 12-Week Endpoint0.26 ± 1.540.09 ± 0.880.14 ± 2.90
Statistical analysis
  • Tadalafil 2.5 mg vs Placebo · Wilcoxin rank-sum · p = 0.060
  • Tadalafil 5 mg vs Placebo · Wilcoxin rank-sum · p = 0.212
SecondaryChange From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint

The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.

Time frame:
Baseline, 54 weeks
Reported as:
Mean · units on a scale
Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in the International Prostate Symptom Score (IPSS) Total Score at 54-Week Endpoint-5.2 ± 5.9-5.4 ± 6.3-6.2 ± 5.4
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint

IPSS storage (irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.

Time frame:
Baseline, 54 weeks
Reported as:
Mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 54-Week Endpoint-1.9 ± 2.5-1.6 ± 2.8-1.8 ± 2.5
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint

IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (not at all) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.

Time frame:
Baseline, 54 weeks
Reported as:
Mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 54-Week Endpoint-3.4 ± 4.1-3.7 ± 4.5-4.3 ± 3.9
SecondaryChange From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint

Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).

Time frame:
Baseline, 54 weeks
Reported as:
Mean · units on a scale
Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in IPSS Quality of Life (QoL) Index at 54-Week Endpoint-0.8 ± 1.2-1.0 ± 1.4-0.9 ± 1.4
SecondaryChange From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint

The OABSS is a four-symptom questionnaire to assess overactive bladder (OAB) symptoms: daytime frequency, nighttime frequency, urgency, and urgency incontinence. Scores range from 0 - 15, with higher scores indicating more severe OAB symptoms.

Time frame:
Baseline, 54 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Overactive Bladder Symptom Score (OABSS) at 54-Week Endpoint-0.9 ± 2.0-1.0 ± 2.4-0.9 ± 2.0
SecondaryChange From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint

Uroflowmetry was assessed by Qmax, defined as the peak urine flow rate (measured in mL/second using a standard calibrated flowmeter).

Time frame:
Baseline, 54 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint
units on a scaleTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 54-Week Endpoint2.29 ± 4.291.51 ± 4.482.01 ± 5.05
SecondaryNumber of Participants With Adverse Events During 42 Weeks of Open-Label Treatment

A listing of Adverse Events are reported in the Reported Adverse Event Section.

Time frame:
End of 12 weeks of double-blind through 54 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events During 42 Weeks of Open-Label Treatment
participantsTadalafil 2.5 mgTadalafil 5 mgPlacebo
Serious Adverse Events344
Non-Serious Adverse Events818194
SecondaryChange From Baseline in Blood Pressure During at 54-Week Endpoint
Time frame:
Baseline, 54 weeks
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Blood Pressure During at 54-Week Endpoint
millimeters of mercury (mmHg)Tadalafil 2.5 mgTadalafil 5 mgPlacebo
Systolic blood pressure-2.1 ± 13.4-1.2 ± 13.2-0.5 ± 14.2
Diastolic blood pressure-1.6 ± 9.6-2.9 ± 9.2-1.3 ± 9.8
SecondaryChange From Baseline in Sitting Heart Rate at 54-Week Endpoint
Time frame:
Baseline, 54-weeks
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Sitting Heart Rate at 54-Week Endpoint
beats per minute (bpm)Tadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Sitting Heart Rate at 54-Week Endpoint1.4 ± 10.40.4 ± 9.32.1 ± 10.6
SecondaryChange From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint

Measurement of nanograms of PSA per milliliter (ng/mL) of blood.

Time frame:
Baseline, 54 weeks
Reported as:
Mean · microgram/liter
Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint
microgram/literTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Prostate Specific Antigen (PSA) at 54-Week Endpoint0.4 ± 1.00.3 ± 0.90.3 ± 1.4
SecondaryChange From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint

Post residual volume (PVR) is measured by ultrasound at regular intervals.

Time frame:
Baseline, 54 weeks
Reported as:
Mean · milliliter
Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint
milliliterTadalafil 2.5 mgTadalafil 5 mgPlacebo
Change From Baseline in Postvoid Residual Volume (PVR) at 54-Week Endpoint-5.7 ± 50.0-1.9 ± 42.9-5.5 ± 46.8

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) - defined as events that 1st occurred/worsened after randomization at Week 0.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil 2.5 mg - Double-Blind Phase—2/142 (1.4%)52/142 (36.6%)
Tadalafil 5 mg - Double-Blind Phase—2/140 (1.4%)54/140 (38.6%)
Placebo - Double-Blind Phase—1/140 (0.7%)53/140 (37.9%)
Tadalafil 2.5 mg: Tadalafil 5 mg Open-Label—3/135 (2.2%)81/135 (60%)
Tadalafil 5 mg: Tadalafil 5 mg Open-Label—4/128 (3.1%)81/128 (63.3%)
Placebo: Tadalafil 5 mg Open-Label—4/131 (3.1%)94/131 (71.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventTadalafil 2.5 mg - Double-Blind PhaseTadalafil 5 mg - Double-Blind PhasePlacebo - Double-Blind PhaseTadalafil 2.5 mg: Tadalafil 5 mg Open-LabelTadalafil 5 mg: Tadalafil 5 mg Open-LabelPlacebo: Tadalafil 5 mg Open-Label
Jaw fractureInjury, poisoning and procedural complications0/1420/1400/1400/1351/1280/131
Traumatic arthritisInjury, poisoning and procedural complications0/1420/1400/1400/1351/1280/131
Back painMusculoskeletal and connective tissue disorders0/1420/1400/1400/1351/1280/131
Urinary retentionRenal and urinary disorders0/1420/1400/1400/1351/1280/131
Colonic polypGastrointestinal disorders0/1420/1400/1400/1350/1281/131
Jaundice cholestaticHepatobiliary disorders0/1420/1400/1400/1350/1281/131
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1420/1400/1400/1350/1281/131
Cerebral infarctionNervous system disorders0/1420/1400/1400/1350/1281/131
Subarachnoid haemorrhageNervous system disorders0/1420/1400/1400/1350/1281/131
Sudden hearing lossEar and labyrinth disorders0/1420/1400/1401/1350/1280/131
Most frequent other events
Showing 10 of 114
Most frequent other events
EventTadalafil 2.5 mg - Double-Blind PhaseTadalafil 5 mg - Double-Blind PhasePlacebo - Double-Blind PhaseTadalafil 2.5 mg: Tadalafil 5 mg Open-LabelTadalafil 5 mg: Tadalafil 5 mg Open-LabelPlacebo: Tadalafil 5 mg Open-Label
NasopharyngitisInfections and infestations11/14214/14018/14025/13515/12819/131
DiarrhoeaGastrointestinal disorders3/1422/1405/1408/13511/12812/131
HeadacheNervous system disorders2/1423/1403/1402/1353/1289/131
Back painMusculoskeletal and connective tissue disorders2/1422/1402/1405/1355/1288/131
ArthralgiaMusculoskeletal and connective tissue disorders0/1421/1402/1401/1352/1287/131
DyspepsiaGastrointestinal disorders2/1424/1400/1404/1356/1285/131
EczemaSkin and subcutaneous tissue disorders0/1420/1403/1402/1353/1286/131
Seasonal allergyImmune system disorders1/1421/1402/1402/1351/1285/131
GastritisGastrointestinal disorders2/1422/1402/1405/1352/1283/131
Reflux oesophagitisGastrointestinal disorders3/1422/1400/1405/1354/1284/131

Baseline characteristics

Age Continuous
Age Continuous(years)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Mean66.4 ± 7.466.9 ± 7.767.0 ± 6.966.8 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Female0000
Male142140140422
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Japanese142140140422
Region of Enrollment
Region of Enrollment(participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Japan142140140422
Baseline (Visit 3) Benign Prostatic Hyperplasia Severity
Baseline (Visit 3) Benign Prostatic Hyperplasia Severity(participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Moderate100102100302
Severe423840120
Current Alcohol Use
Current Alcohol Use(participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Yes969293281
No464847141
Current Tobacco Use
Current Tobacco Use(participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Yes31282584
No617270203
Unknown or Not Recorded504045135
Previous Alpha-blocker Use
Previous Alpha-blocker Use(participants)Tadalafil 2.5 mgTadalafil 5 mgPlaceboTotal
Yes111108106325
No31323497

7 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 274-0825, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hiroshima, 730-0013, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 226-0025, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyoto, 607-8085, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 561-0832, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 150-0002, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Jun 2009 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2008
First posted
Oct 31, 2008
Start
Nov 2008
Primary completionActual
Jun 2009
CompletionActual
Apr 2010
Results first posted
Jul 28, 2010
Last update
Mar 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00783094
First posted
Oct 31, 2008
Start date
Nov 2008
Primary completion
Jun 2009
Completion
Apr 2010
Results posted
Jul 28, 2010
Last update
Mar 29, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion